Episode 1: Inari Medical: Clot Warriors—Changing the Paradigm in DVT and Pulmonary Embolism
SEPTEMBER 30, 12:00 – 1:00 pm EDT
Fox Rothschild’s MedTech attorneys are part of an AmLaw 100 firm with 950 lawyers in 70 practice areas coast-to-coast. Entrepreneurial, resourceful, and innovative, Fox attorneys listen, then act on what they hear, delivering national firm resources with the focus and service of a boutique, and an unwavering commitment to client satisfaction.
The Medtech Conference is well-known for gathering the leading innovators, investors, and executives from around the nation to discuss the timeliest issues and opportunities. Covid19 forced us to postpone this year’s in-person event, but we didn’t want the helpful and impactful conversations our audience enjoys to stop; hence we’re launching the Medtech Talk Digital Discussion Series. Like the conference, this series will feature discussions (panels or fireside chats) hosted by moderator Geoff Pardo that explore relevant topics for medtech leaders.
This first episode will feature an exclusive panel interview with several members of the Inari Medical management team. The team will discuss their unique culture, strong mission, early success, sales strategy and many other topics. As one of medtech’s startup success stories, particularly with achieving an IPO during this pandemic, you will not want to miss this conversation!
Patrice Kloss, Partner, Fox Rothschild LLP
Moderator: Geoff Pardo, General Partner, Gilde Healthcare; Host, Medtech Talk podcast
Bill Hoffman, CEO, Inari Medical, Inc.
Drew Hykes, CCO, Inari Medical, Inc.
Thomas Tu, MD, CMO, Inari Medical, Inc.
Tara Dunn, Vice President of Clinical Affairs and Market Development, Inari Medical, Inc.
Patrice Kloss of Fox Rothschild LLP is Co-Chair of Fox’s national Medical Technology practice group and leads the Corporate team in Minneapolis. Patrice advises medical technology companies, digital health care companies, other emerging businesses and venture capital investors in a broad range of commercial and financing matters, including venture capital financings, private placements, mergers and acquisitions, venture debt and credit facilities, and securities compliance. Patrice also guides lenders in commercial loan transactions, including $100 million+ loan facilities, and advises clients on equity financing structures and clinical trial agreements.
Geoff Pardo joined Gilde Healthcare in 2011 as a Partner working out of the office in Boston/Cambridge, MA and is focusing on Gilde’s investments in North America. He led the investments in Inari Medical, Axonics Modulation Technologies, CVRx, InovaLabs (acquired by ResMed), BionX (acquired by Ottobock) and Vapotherm and represents Gilde as a member of the board of directors for each company. Previously, he was a Partner at Spray Venture Partners where he led investments into Interlace Medical (sold to Hologic), Solace Therapeutics, TearScience (sold to J&J) and Cascade Ophthalmics. He served on the board of Solace, TearScience and Cascade, and was actively involved in Interlace and Conventus Orthopedics. Geoff also served as President & CEO of Facet Solutions, a spinal implant company focused on treating lumbar spinal stenosis until the company was sold to Globus Medical in 2011. He has also worked at Cardinal Partners as an Associate leading their investing activity in the medical device sector. Geoff began his career in medical devices as a product manager with Synthes USA, and he has a BA with honors in History from Brown University and an MBA from the Wharton School of Business. He is a US citizen based in Gilde Healthcare’s Cambridge, MA office.
Bill has focused on early stage companies with novel devices in new markets. Prior to Inari Medical, Bill served as CEO of Visualase, Inc., which developed and sold lasers for minimally invasive neurosurgery. The company was acquired by Medtronic for $105M in July, 2014, having raised less than $10m in equity funding. Prior to Visualase, Bill was Vice President of Sales at FoxHollow, Inc., helping to build a commercial team and revenue ramp that led to a successful IPO in 2004 and an acquisition by EV3 in 2007. Bill’s first early stage med tech experience was as head of sales at RITA Medical Systems, an interventional oncology company that enjoyed a successful IPO in 2000. He spent the early part of his career in various sales roles at Ethicon and Medtronic.
Drew is a proven medical device operating executive with broad functional, geographic and sector experience. From 2012-2016 Drew served as the VP of Commercial Operations at Sequent Medical where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market. Sequent was acquired by Terumo Corporation in July 2016 for $380 million. Prior to Sequent, Drew spent 11 years at Medtronic. His roles at Medtronic included the VP of Marketing for the AF Solutions business, VP of Clinical and Regulatory for the AF Solutions business and Director of Investor Relations. Drew also spent three years on an expatriate assignment in Europe leading the launch of Medtronic’s first drug eluting coronary stent. Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions. He earned a B.B.A. in Finance from the University of Wisconsin and an MBA from Harvard Business School.
Tom Tu, MD
Dr. Thomas Tu joins Inari Medical after practicing Interventional Cardiology for 16 years. He is a graduate of Harvard Medical School and completed residency at Massachusetts General Hospital. He was trained in Interventional Cardiology, Peripheral Vascular Intervention, and Structural Heart Disease at Beth Israel Deaconess Medical Center. Most recently, he was the Cath Lab director and leader of the Pulmonary Embolism, complex PCI, and TAVR programs at Baptist Health Louisville. Dr. Tu helped develop the early phase technology that allowed Inari Medical to optimize patient outcomes. He also served as the presenter for the FLARE IDE trial of the Inari FlowTriever Retrieval/Aspiration System. This study led to FDA 510 (k) clearance for treatment of pulmonary embolism, the first thrombectomy device cleared for that indication.